Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-09-06
2005-09-06
Weber, Jon (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S021800, C424S184100, C424S236100, C424S247100, C530S350000, C604S058000
Reexamination Certificate
active
06939852
ABSTRACT:
The invention provides for the use of abotulinumtoxin to treat cerebral palsy in juvenile patients by transdermal administration of thebotulinumtoxin. The juvenile patients are preferably juveniles of up to 6 years in age.
REFERENCES:
patent: 4932936 (1990-06-01), Dykstra et al.
patent: 5053005 (1991-10-01), Borodic
patent: 5298019 (1994-03-01), Borodic
patent: 6395277 (2002-05-01), Graham
patent: 6448231 (2002-09-01), Graham
patent: 19852981 (2000-05-01), None
Bodde H.E., et al., Transdermal Peptide Delivery, Biochem Soc Trans 17(5);943-5: 1989.
Botulinum toxin may be useful in range of muscular disorders, Int Med News 1991 Aug. 15;24(16):36 Author unknown (Abstract).
Brin, M., et al., Assessment: The clinical usefulness of botulinum toxin-A in treating neurologic disorders, Neurology 1990;40:1332-1336.
Choi, H-K, et al., Transdermal delivery of bioactive peptides: the effect of n-decylmethyl sulfoxide, pH, and inhibitors on Enkephalin metabolism and transport, Pharm Res 7(11):1099-1106 (1990).
Cioffi, G.A., et al., Microvasculature of the Anterior Optic Nerve, Survey of Opthalmology, vol. 38, Suppl., May 1994.
Consensus Conference, Clinical Use of Botulinum Toxin, Connecticut Medicine, vol. 55, No. 8, pp 471-477 (1991).
Clinical Use of Botulinum Toxin, NIH Consens Statement, 1990 Nov. 12-14; 8(8):1-20.
Cosgrove et al., Botulinum toxin A prevents the development of contractures in the hereditary spastic mouse model, Dev Med and Child Neurol. 1994, 36, 379-385.
Cosgrove et al., Botulinum toxin in the management of lower limb in cerebral palsy, Dev Med and Child Neurol. 1994, 36, 386-396.
Das, T.K., et al. Effect of treatment with botulinum toxin on spasticity, Postgraduate Medical Journal (1989) 65,208-210.
Duane, D.D., Spasmodic Torticollis, In: Jankovic J., ed., Advances in Neurology, vol. 49, Facial Dyskinesias, NY, Raven Press; 1988:pp 135-50 (Abstract).
Dunn, W.J., et al., Botulinum Toxin for the Treatment of Dysthyroid Ocular Myopathy, Ophthalmology, vol. 93, No. 4, Apr. 1986, pp. 470-475.
Hatheway, C.L., Bacterial Sources of Clostridial Neurotoxins, Chapter 1, pp. 3-24, L.L. Simpson, editor, Botulinum Neurotoxin and Tetanus Toxin, Academic Press, Inc. 1989.
Jankovic, J. et al., Therapeutic Uses of Botulinum Toxin, The New England Journal of Medicine, vol. 324, Apr. 25, 1991, No. 17, pp 1186-1194.
Liedtke, R.K., et al., Transdermal administration of insulin in type II diabetes, Results of a clinical pilot study; Arneimittelforschung 40(8); 884-6:1990 (German) (English abstract).
Overmyer, R.H., Botulinum toxin: poison with a purpose, Mod Med Sep. 1991;59:112-6 (Abstract).
Park et al., Binding ofClostridium botulinumtype B toxin to rat brain synaptosome, Fems Microbiol Lett., 1990; 60(3):243-7. (Abstract).
Rosenbaum, A.L., et al., Vertical rectus muscle transposition and botulinum toxin (Oculinum) to medical rectus for abducens palsy, Arch Ophthalmol Jun. 1989; 107(6):820-3, (Abstract).
Sanders, L.M., Drug delivery systems and routs of administration of peptide and protein drugs, Eur J of Drug Metabolism and Pharmacokinetics, 1990, vol. 12, No. 2, pp. 95-102.
Sasaki, H. et al., Effect of pyrrolidone derivatives on lipid membrane and protein conformation as transdermal penetration enhancer, J. Pharmacobio-Dyn., 13; 468-474: 1990.
Sato et al., Purification and some properties of a proteinase and an esterase released fromClostridium botulinumA, B, and F types, Nippon Saikingaku Zasshi 1973; 28(4):367-74. (Abstract Only).
Schwartz, B., Circulatory Defects of the Optic Disk and Retina in Ocular Hpertension and High Pressure Open-Angle Glaucoma, Survey of Ophthalmology, vol. 38, Suppl. May 1994.
Scott, A.B., et al., Botulinum Toxin Injection in the Management of Lateral Rectus Paresis, Ophthalmology, vol. 92, No. 5, May 1985, pp. 676-683.
Snow, B.J., et al., Treatment of Spasticity with Botulinum Toxin: A Double-Blind Study, Annals of Neurology, vol. 28, No. 4, Oct. 1990, pp. 512-515.
Srinivasan, V., et al., Iontophoresis of polypeptides: effect of ethanol pretreatment of human skin, J. Pharm Sci 79(7), Jul. 1990.
Tonnesen, P., et al., A double blind trial of a 16-hour transdermal nicotine patch in smoking cessation, New Eng J Medicine, 325(5); 311-315:Aug. 1991.
Verhoef, J.C., et al., Transport of peptide and protein drugs across biological membranes, Eur J Drug Metab Pharmacokinet 1990, Apr.-Jun.;15(2):83-93.
Wright, James, et al,The Spastic Mouse and the search for an animal model of spasticity in human beings, Clinical Orthop. and Related Research, Apr. 1990, No. 253, pp. 12-19.
Allergan Inc.
Donovan Stephen
Mohamed Abdel A.
Weber Jon
LandOfFree
Methods and compositions for the treatment of cerebral palsy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for the treatment of cerebral palsy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for the treatment of cerebral palsy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3390994